دورية أكاديمية
أعرض في EDS

Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR-mutated lung adenocarcinoma.

التفاصيل البيبلوغرافية
العنوان: Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR-mutated lung adenocarcinoma.
المؤلفون: Castañeda-Zárraga A; Department of Dermatology, Hospital General Dr. Manuel Gea Gónzalez, Mexico City, Mexico., Rodríguez-Cid JR; Department of Oncology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico., Flores-Mariñelarena RR; Department of Internal Medicine, Fundación Clínica Médica Sur, Mexico City, Mexico., Trinidad-Bibiano H; Department of Pathology, Hospital General Dr. Manuel Gea Gónzalez, Mexico City, Mexico., Martínez-Herrera JF; Department of Oncology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico., Sánchez-Ríos CP; Department of Oncology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico., Fernández-Garibay VM; School of Medicine, Monterrey Institute of Technology and Higher Education, Mexico City, Mexico., Alatorre-Alexander JA; Department of Oncology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico., Martínez-Barrera L; Department of Oncology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico., Santillán-Doherty PJ; Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico., Vega-Memije ME; Department of Dermatology, Hospital General Dr. Manuel Gea Gónzalez, Mexico City, Mexico.
المصدر: Thoracic cancer [Thorac Cancer] 2020 Nov; Vol. 11 (11), pp. 3243-3251. Date of Electronic Publication: 2020 Oct 05.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-7714 (Electronic) Linking ISSN: 17597706 NLM ISO Abbreviation: Thorac Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: November 2012- : Singapore : Tianjin : Wiley Publishing Asia Pty Ltd ; Tianjin Lung Cancer Institute
Original Publication: Richmond, Vic. : Tianjin : Blackwell Pub. Asia Pty Ltd. ; Tianjin Lung Cancer Institute
مواضيع طبية MeSH: Adenocarcinoma of Lung/*drug therapy , Biomarkers/*metabolism , Lung Neoplasms/*drug therapy , Protein Kinase Inhibitors/*therapeutic use , Skin/*pathology, Adenocarcinoma of Lung/pathology ; Female ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prospective Studies ; Protein Kinase Inhibitors/pharmacology
مستخلص: Background: A relationship between the EGFR signaling pathway expression in skin and the use of targeted cancer therapies has been previously demonstrated. Consistent evidence to support the use of skin biopsies as a surrogate for therapeutic evaluation is needed. The purpose of this study was to establish the relationship between the expression of EGFR signaling pathway markers in skin samples from EGFR-mutated metastatic lung adenocarcinoma patients and their response to tyrosine kinase inhibitors.
Methods: This was a prospective single blind analysis of 35 skin biopsies from 31 patients with confirmed advanced EGFR-mutated lung adenocarcinoma. Immunohistochemistry was performed: EGFR, p27, Ki67, STAT3 and MAPK, as well as H&E histopathological analysis, in order to determine their treatment response to tyrosine kinase inhibitors.
Results: EGFR, Ki67, STAT3, stratum corneum thickness (number of layers and millimeters) from skin samples had a statistical correlation with an adequate treatment response (P = 0.025, 0.015, 0.017, 0.041, 0.039 respectively). EGFR, p27 and number of layers of the stratum corneum were related to a better median progression-free survival (P = 0.025 and P = 0.030).
Conclusions: The relationship between EGFR pathway inhibition in the skin and oncological outcomes obtained explains the parallel biological effects of tyrosine kinase inhibitors. We hope that our work incites future research to help validate and assess the use of these markers as potential prognostic and predictive factors.
(© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
References: J Clin Pathol. 2007 Oct;60(10):1112-6. (PMID: 17182662)
Nat Rev Cancer. 2006 Oct;6(10):803-12. (PMID: 16990857)
Lancet Oncol. 2016 May;17(5):577-89. (PMID: 27083334)
Int J Cancer. 2010 Feb 1;126(3):651-5. (PMID: 19609951)
CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949)
J Clin Oncol. 2005 Aug 1;23(22):5235-46. (PMID: 16051966)
J Biol Chem. 2001 Mar 2;276(9):6320-6. (PMID: 11098053)
J Oncol. 2009;2009:849051. (PMID: 19584908)
Eur J Cancer. 2010 Jul;46(11):2010-9. (PMID: 20621734)
Oncologist. 2005 May;10(5):345-56. (PMID: 15851793)
J Clin Oncol. 2003 May 15;21(10):1980-7. (PMID: 12743152)
Nat Rev Cancer. 2008 Apr;8(4):253-67. (PMID: 18354415)
Cancer Res. 2003 Jan 1;63(1):1-5. (PMID: 12517767)
Clin Lung Cancer. 2003 May;4(6):366-9. (PMID: 14599302)
Mol Cancer Ther. 2005 Apr;4(4):650-8. (PMID: 15827339)
JAMA. 2003 Oct 22;290(16):2149-58. (PMID: 14570950)
Sci Transl Med. 2013 Aug 21;5(199):199ra110. (PMID: 23966299)
N Engl J Med. 2008 Mar 13;358(11):1160-74. (PMID: 18337605)
Br J Dermatol. 2001 Jun;144(6):1169-76. (PMID: 11422037)
J Dermatol Sci. 2013 Nov;72(2):81-6. (PMID: 23819985)
Sci Transl Med. 2013 Aug 21;5(199):199ra111. (PMID: 23966300)
J Clin Oncol. 2002 Jan 1;20(1):110-24. (PMID: 11773160)
Br J Dermatol. 2002 Sep;147(3):598-601. (PMID: 12207609)
Cell Growth Differ. 1998 Oct;9(10):847-55. (PMID: 9790496)
Arch Toxicol. 2014 Jun;88(6):1189-203. (PMID: 24770552)
J Cutan Pathol. 2013 Oct;40(10):865-70. (PMID: 23941617)
J Invest Dermatol. 1997 Dec;109(6):751-6. (PMID: 9406816)
J Am Acad Dermatol. 2006 Oct;55(4):657-70. (PMID: 17010747)
Am J Pathol. 1997 Jun;150(6):1959-75. (PMID: 9176390)
J Cutan Pathol. 2016 Mar;43(3):211-8. (PMID: 26423594)
J Thorac Oncol. 2015 Sep;10(9):1240-1242. (PMID: 26291007)
Eur J Cancer. 2006 May;42(8):1031-9. (PMID: 16616487)
Br J Dermatol. 2011 Jan;164(1):38-46. (PMID: 20846305)
Rev Invest Clin. 2013 Mar;65 Suppl 1:S5-84. (PMID: 24459776)
فهرسة مساهمة: Keywords: Biomarkers; EGFR; NSCLC; skin biopsy
المشرفين على المادة: 0 (Biomarkers)
0 (Protein Kinase Inhibitors)
تواريخ الأحداث: Date Created: 20201005 Date Completed: 20210806 Latest Revision: 20210806
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7606021
DOI: 10.1111/1759-7714.13657
PMID: 33015988
قاعدة البيانات: MEDLINE
الوصف
تدمد:1759-7714
DOI:10.1111/1759-7714.13657